Herbert Stadler

Dr. Herbert Stadler is publicly identified as the founder of IBA Lifesciences GmbH, a Göttingen, Germany-based biotechnology company. IBA was founded in 1996 as Institut für Bioanalytik GmbH and later renamed IBA GmbH in 2001. The company built its business around Strep-tag / Strep-Tactin technology for protein purification and analysis, with later applications in cell selection.

IBA Lifesciences describes itself as a provider of life-science research products for academia and industry, developing high-performance research tools for cell and protein isolation based on proprietary Strep-tag technology. The company’s products are distributed through a global network covering more than 40 countries across five continents.

The public record links Stadler most concretely to company formation and executive leadership at IBA Lifesciences. IBA’s historical profile names him as founder and president, while current IBA materials show the company became part of Cube Biotech Group in January 2025.

I found the supplied Stage Cell Therapeutics email domain in the stub, but I could not independently verify that email address, a current Stage Cell Therapeutics website, or a public investor profile for Stadler from accessible primary sources.

• No public investment thesis, check-size statement, or founder-facing investment criteria for Dr. Stadler was found in accessible sources.
• The strongest evidence of sector focus is his operating history: IBA Lifesciences’ platform is centered on Strep-tag / Strep-Tactin technology for protein purification, protein analysis, and cell isolation.
• A likely fit, based on documented operating experience rather than a published thesis, would be early life-science tools, cell-selection, protein-analysis, and cell-therapy enabling technologies.
• IBA’s current company description emphasizes products for life-science research in academia and industry, global distribution, and tools for cell and protein isolation.